Eribulin mesylate (Halaven)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Eribulin mesylate (Halaven), covering 2013-12-10 to 2025-11-06. Get the full timeline:
Most recent: Clinical Trial Update: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer [Phase 2]